{"id":"W4280518749","doi":"10.1016/j.ejca.2022.04.016","title":"Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study","year":2022,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":true,"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Alberta","funders":"National Cancer Institute; Foundation Medicine; Eisai; Merck Sharp and Dohme; Ipsen; Astellas Pharma; Sanofi; Chugai Pharmaceutical; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Prostate cancer; Tolerability; Olaparib; Medicine; Adverse effect; Oncology; Internal medicine; Cancer; Gynecology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008086258,0.0001411662,0.0003074087,0.00008879394,0.0001619077,0.00003172275,0.0001332356,0.000003712051,0.0002523212],"category_scores_gemma":[0.000007631436,0.00007674392,0.00005110379,0.0002617494,0.00007558346,0.0000959241,0.00009283875,0.0003204079,7.728624e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00040768,"about_ca_system_score_gemma":0.0001684707,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007750136,"about_ca_topic_score_gemma":0.001112747,"domain_scores_codex":[0.9977035,0.0007083215,0.0004643736,0.0001969071,0.000739794,0.0001871281],"domain_scores_gemma":[0.9992037,0.0000470555,0.0003051186,0.000197412,0.000155271,0.00009148195],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.007077732,0.001098966,0.9600521,0.00003796698,0.001248502,0.0007200398,0.006120684,0.001588868,0.00007879436,0.000001375407,0.0002312795,0.02174367],"study_design_scores_gemma":[0.01007694,0.002335535,0.9780029,0.0001154349,0.0005403947,0.000002984137,0.006919205,0.0000212554,0.00003469632,0.00001000568,0.00185544,0.00008517587],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9932736,0.003334574,0.000002794308,0.001708754,0.00009838308,0.001276875,0.00008100728,0.000004304653,0.000219771],"genre_scores_gemma":[0.9990087,0.0002625251,0.00007634737,0.0001417763,0.00004384304,0.00007434296,0.00001153525,0.00002243775,0.0003584839],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0216585,"threshold_uncertainty_score":0.3129526,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04573720873806924,"score_gpt":0.3604040520670452,"score_spread":0.3146668433289759,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}